Track record · closed signal

Aurinia Pharmaceuticals Inc (AUPH) — closed signal from March 31, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on June 29, 2026 — +15.4% at the close.

Predicted vs. what happened

AUPH price · publication thesis → realized outcomesplit-adjusted

$13.80 – $14.90Entry zone — fair-value band

$14.55Published — price the day we called it

$16.00Target — the price the thesis aimed for

$19.25Peak — highest point inside the window, not a realized return

$16.79Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 6 days.

At window close

+15.4%

realized, from the publication price to the last close inside the window

Peak gain

+32.3%

peak, from the publication price — not a realized return

S&P 500, same window

+14.2%

SPY over the identical days, dividend-adjusted

Window close

$16.79

last close inside the window, ended June 29, 2026

Peak price

$19.25

peak on June 24, 2026 — not a realized return

Days to target

The thesis — published March 31, 2026

Predicted growth

+10%

over the measurement window

Target price

$16.00

the price the thesis aimed for

Entry zone

$13.80 – $14.90

the fair-value band we waited for

Price at publication

$14.55

published March 31, 2026

Confidence

63%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Aurinia looks like a short-term special situation: a recent acquisition and management change could lift expectations, but much depends on the deal going smoothly and investors trusting management choices. Trading is light, so the stock can move sharply. Cash and a low valuation give some cushion, but overall confidence is limited.

Primary drivers

The Kezar deal creates a clear near-term event that could change sentiment
New management can change expectations about strategy and spending
A strong cash position and low valuation help limit downside
Thin trading and deal execution risk make the setup less reliable

How it played out

AUPH: target reached in 6 days

Lyra published AUPH at $14.55 with an expected gain of 10% and a $16 target. The thesis pointed to the Kezar deal, new management, cash, and a low valuation. It also noted that thin trading and deal execution made the setup less reliable.

The stock reached the target in 6 days. It later peaked at $19.25 on June 24, a gain of 32.3%. It ended the window at $16.79 on June 29, still above the target. The thesis played out and exceeded its stated price objective.

What happened during the window

On May 7, Aurinia reported first-quarter revenue of $77.7 million, up 24% from the same period in 2025. On May 11, the company completed its acquisition of Kezar Life Sciences.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All AUPH signals